{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:02:00Z","timestamp":1790899320572,"version":"4.1.0"},"reference-count":167,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-02362708"],"award-info":[{"award-number":["RF-02362708"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["SG-12358253"],"award-info":[{"award-number":["SG-12358253"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","award":["22522"],"award-info":[{"award-number":["22522"]}],"id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["Intramural Research"],"award-info":[{"award-number":["Intramural Research"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer treatment has made significant progress in the cure of different types of tumors. Nevertheless, its clinical use is limited by unwanted cardiotoxicity. Aside from the conventional chemotherapy approaches, even the most newly developed, i.e., molecularly targeted therapy and immunotherapy, exhibit a similar frequency and severity of toxicities that range from subclinical ventricular dysfunction to severe cardiomyopathy and, ultimately, congestive heart failure. Specific mechanisms leading to cardiotoxicity still remain to be elucidated. For instance, oxidative stress and DNA damage are considered key players in mediating cardiotoxicity in different treatments. microRNAs (miRNAs) act as key regulators in cell proliferation, cell death, apoptosis, and cell differentiation. Their dysregulation has been associated with adverse cardiac remodeling and toxicity. This review provides an overview of the cardiotoxicity induced by different oncologic treatments and potential miRNAs involved in this effect that could be used as possible therapeutic targets.<\/jats:p>","DOI":"10.3390\/cancers12030704","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T10:01:35Z","timestamp":1584612095000},"page":"704","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["MicroRNAs in Cancer Treatment-Induced Cardiotoxicity"],"prefix":"10.3390","volume":"12","author":[{"given":"Laura","family":"Pellegrini","sequence":"first","affiliation":[{"name":"Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sileno","sequence":"additional","affiliation":[{"name":"Istituto Dermopatico dell\u2019Immacolata, IDI-IRCCS, Experimental Immunology Laboratory, Via dei Monti di Creta 104, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"Istituto Dermopatico dell\u2019Immacolata, IDI-IRCCS, Experimental Immunology Laboratory, Via dei Monti di Creta 104, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Foglio","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Florio","sequence":"additional","affiliation":[{"name":"Laboratory of Cardiovascular Science, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Guzzanti","sequence":"additional","affiliation":[{"name":"Istituto Dermopatico dell\u2019Immacolata, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Antonio","family":"Russo","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Pisana and MEBIC Consortium, 00166 Rome, Italy"},{"name":"San Raffaele Open University, 00166 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Limana","sequence":"additional","affiliation":[{"name":"San Raffaele Open University, 00166 Rome, Italy"},{"name":"Laboratory of Cellular and Molecular Pathology, IRCCS San Raffaele Pisana, 00166 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9054-337X","authenticated-orcid":false,"given":"Alessandra","family":"Magenta","sequence":"additional","affiliation":[{"name":"Istituto Dermopatico dell\u2019Immacolata, IDI-IRCCS, Experimental Immunology Laboratory, Via dei Monti di Creta 104, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: Target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrg2936","article-title":"Gene silencing by microRNAs: Contributions of translational repression and mRNA decay","volume":"12","author":"Huntzinger","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ncb0309-228","article-title":"Many roads to maturity: microRNA biogenesis pathways and their regulation","volume":"11","author":"Winter","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_4","first-page":"138","article-title":"Extracellular\/circulating microRNAs and their potential role in cardiovascular disease","volume":"1","author":"Zhu","year":"2011","journal-title":"Am. J. Cardiovasc. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"239ps3","DOI":"10.1126\/scitranslmed.3009008","article-title":"MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease","volume":"6","author":"Olson","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/med.21463","article-title":"Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights","volume":"38","author":"Zheng","year":"2018","journal-title":"Med. Res. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fcvm.2018.00009","article-title":"Cardiotoxicity of Anticancer Therapeutics","volume":"5","author":"Dong","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11886-017-0846-x","article-title":"Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions","volume":"19","author":"Jain","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_11","first-page":"865","article-title":"Anthracycline cardiomyopathy monitored by morphologic changes","volume":"62","author":"Billingham","year":"1978","journal-title":"Cancer Treat. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","article-title":"Cardiotoxicity of anticancer treatments: What the cardiologist needs to know","volume":"7","author":"Ewer","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: Importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1089\/ars.2016.6930","article-title":"From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview","volume":"30","author":"Tocchetti","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd3252","article-title":"Cardiotoxicity of kinase inhibitors: The prediction and translation of preclinical models to clinical outcomes","volume":"10","author":"Force","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-017-0034-x","article-title":"Precision cardio-oncology: Understanding the cardiotoxicity of cancer therapy","volume":"1","author":"Han","year":"2017","journal-title":"NPJ Precis. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2","volume":"70","author":"Chang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Smith, L.A., Cornelius, V.R., Plummer, C.J., Levitt, G., Verrill, M., Canney, P., and Jones, A. (2010). Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-337"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Guyot, A., Ortonne, N., Valeyrie-Allanore, L., and Bagot, M. (2010). Combined Treatment With Rituximab and Anthracycline-Containing Chemotherapy for Primary Cutaneous Large B-Cell Lymphomas, Leg Type, in Elderly Patients. Arch. Dermatol., 146.","DOI":"10.1001\/archdermatol.2009.345"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s10147-012-0411-y","article-title":"Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma","volume":"18","author":"Nakamura","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K","article-title":"Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia","volume":"20","author":"Tan","year":"1967","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/clc.22672","article-title":"The influence of chemotherapy on the right ventricle: Did we forget something?","volume":"40","author":"Tadic","year":"2017","journal-title":"Clin. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00395-013-0334-4","article-title":"Doxorubicin induces senescence and impairs function of human cardiac progenitor cells","volume":"108","author":"Piegari","year":"2013","journal-title":"Basic Res. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"62312","DOI":"10.18632\/oncotarget.11468","article-title":"MicroRNA-34a regulates doxorubicin-induced cardiotoxicity in rat","volume":"7","author":"Piegari","year":"2016","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mito.2016.07.005","article-title":"Cardiac cytochrome c and cardiolipin depletion during anthracycline-induced chronic depression of mitochondrial function","volume":"30","author":"Pereira","year":"2016","journal-title":"Mitochondrion"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00000421-198212000-00015","article-title":"Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy","volume":"5","author":"Dresdale","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.freeradbiomed.2003.08.005","article-title":"The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin","volume":"35","author":"Hasinoff","year":"2003","journal-title":"Free Radic. Biol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"ref_37","first-page":"743193","article-title":"The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy","volume":"2012","author":"Mitri","year":"2012","journal-title":"Chemother. Res. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1200\/JCO.2010.30.6274","article-title":"Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction","volume":"28","author":"Ewer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.ejca.2007.06.024","article-title":"111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity","volume":"43","author":"Jager","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/jdv.12327","article-title":"Intralesional bevacizumab as in-add adjuvant to immunocryosurgery for locally advanced basal cell carcinoma","volume":"28","author":"Gaitanis","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","article-title":"Bevacizumab increases the risk of arterial ischemia: A large study in cancer patients with a focus on different subgroup outcomes","volume":"22","author":"Schutz","year":"2011","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bcpt.12365","article-title":"The adverse effects of sorafenib in patients with advanced cancers","volume":"116","author":"Li","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1172\/JCI39434","article-title":"Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress","volume":"120","author":"Chintalgattu","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"Guilhot","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Grazette","year":"2006","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","article-title":"Drug-induced mitochondrial dysfunction and cardiotoxicity","volume":"309","author":"Varga","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/VHRM.S108874","article-title":"Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: Preventive strategies and cardiovascular surveillance","volume":"13","author":"Aghel","year":"2017","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09059180.00003313","article-title":"Drug-induced pulmonary arterial hypertension: A recent outbreak","volume":"22","author":"Montani","year":"2013","journal-title":"Eur. Respir. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Rix","year":"2009","journal-title":"Leukemia"},{"key":"ref_55","first-page":"1","article-title":"Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: Patient selection and perspectives","volume":"8","author":"Anagnostou","year":"2018","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.21037\/atm.2016.04.01","article-title":"Harnessing the immune system to improve cancer therapy","volume":"4","author":"Papaioannou","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/intimm\/dxz012","article-title":"Immunotherapy for skin cancer","volume":"31","author":"Paulson","year":"2019","journal-title":"Int. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0377-1237(10)80132-7","article-title":"Radiotherapy: Basic Concepts and Recent Advances","volume":"66","author":"Mehta","year":"2010","journal-title":"Med. J. Armed Forces India"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0360-3016(01)01656-X","article-title":"Radiotherapy for epithelial skin cancer","volume":"51","author":"Locke","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/01.HP.0000326334.64242.46","article-title":"New technologies in radiation therapy: Ensuring patient safety, radiation safety and regulatory issues in radiation oncology","volume":"95","author":"Amols","year":"2008","journal-title":"Health Phys."},{"key":"ref_61","first-page":"139","article-title":"X-ray imaging physics for nuclear medicine technologists. Part 1: Basic principles of X-ray production","volume":"32","author":"Seibert","year":"2004","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.7150\/ijbs.35460","article-title":"Radiation-induced heart disease: A review of classification, mechanism and prevention","volume":"15","author":"Wang","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4330\/wjc.v8.i9.504","article-title":"Novel concepts in radiation-induced cardiovascular disease","volume":"8","author":"Cuomo","year":"2016","journal-title":"World J. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ctrv.2003.07.003","article-title":"Cardiotoxicity of cytotoxic drugs","volume":"30","author":"Schimmel","year":"2004","journal-title":"Cancer Treat. Rev."},{"key":"ref_65","first-page":"1","article-title":"Clinical toxicities encountered with paclitaxel (Taxol)","volume":"20","author":"Rowinsky","year":"1993","journal-title":"Semin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.15420\/icr.2019.12","article-title":"Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions","volume":"14","author":"Chong","year":"2019","journal-title":"Interv. Cardiol. (Lond. Engl.)"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2018.03.022","article-title":"Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence","volume":"828","author":"Gavazzoni","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12012-007-0013-5","article-title":"Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes","volume":"7","author":"Gianni","year":"2007","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_69","first-page":"36","article-title":"Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer","volume":"17","author":"Zielinski","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.tox.2016.04.010","article-title":"Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes","volume":"353\u2013354","author":"Spur","year":"2016","journal-title":"Toxicology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2011.40.3584","article-title":"Screening adult survivors of childhood cancer for cardiomyopathy: Comparison of echocardiography and cardiac magnetic resonance imaging","volume":"30","author":"Armstrong","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(05)01719-5","article-title":"Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity","volume":"6","author":"Jones","year":"2005","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Caspi, O., and Aronson, D. (2019). Surviving Cancer without a Broken Heart. Rambam Maimonides Med. J., 10.","DOI":"10.5041\/RMMJ.10366"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Fr\u00e8res, P., Bouznad, N., Servais, L., Josse, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., and Lancellotti, P. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4015-4"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11879","DOI":"10.1038\/s41598-017-12192-y","article-title":"Activation of miR-34a-5p\/Sirt1\/p66shc pathway contributes to doxorubicin-induced cardiotoxicity","volume":"7","author":"Zhu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Hu, Y., Xia, W., and Hou, M. (2018). Macrophage migration inhibitory factor serves a pivotal role in the regulation of radiation-induced cardiac senescencethrough rebalancing the microRNA-34a\/sirtuin 1 signaling pathway. Int. J. Mol. Med.","DOI":"10.3892\/ijmm.2018.3838"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.critrevonc.2016.11.017","article-title":"Emergence of miR-34a in radiation therapy","volume":"109","author":"Lacombe","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/ijms15010927","article-title":"The effect of radiation on the immune response to cancers","volume":"15","author":"Park","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.cardiores.2005.08.009","article-title":"Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase","volume":"69","author":"Spallarossa","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jacbts.2018.10.006","article-title":"miR-29b Mediates the Chronic Inflammatory Response in Radiotherapy-Induced Vascular Disease","volume":"4","author":"Eken","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1161\/CIRCRESAHA.108.193250","article-title":"A novel role of microRNA in late preconditioning: Upregulation of endothelial nitric oxide synthase and heat shock protein 70","volume":"104","author":"Yin","year":"2009","journal-title":"Circ. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"29514","DOI":"10.1074\/jbc.M109.027896","article-title":"MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction","volume":"284","author":"Dong","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/cvr\/cvp015","article-title":"MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue","volume":"82","author":"Roy","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nature07511","article-title":"MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts","volume":"456","author":"Thum","year":"2008","journal-title":"Nature"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4149\/gpb_2015038","article-title":"Myocardial connexin-43 and PKC signalling are involved in adaptation of the heart to irradiation-induced injury: Implication of miR-1 and miR-21","volume":"35","author":"Viczenczova","year":"2016","journal-title":"Gen. Physiol. Biophys."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.prp.2018.12.007","article-title":"Association between miR-21\/146a\/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study","volume":"215","author":"Kopcalic","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1536\/ihj.50.377","article-title":"MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2","volume":"50","author":"Tang","year":"2009","journal-title":"Int. Heart J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bbrc.2009.02.097","article-title":"Upregulated expression of miR-1\/miR-206 in a rat model of myocardial infarction","volume":"381","author":"Shan","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_91","first-page":"27","article-title":"MicroRNA miR-1 is up-regulated in remote myocardium in patients with myocardial infarction","volume":"56","author":"Bostjancic","year":"2010","journal-title":"Folia Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/597032","article-title":"MicroRNA-208a Silencing Attenuates Doxorubicin Induced Myocyte Apoptosis and Cardiac Dysfunction","volume":"2015","author":"Tony","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/jat.3185","article-title":"Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"35","author":"Ferreira","year":"2015","journal-title":"J. Appl. Toxicol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.taap.2014.10.006","article-title":"Early biomarkers of doxorubicin-induced heart injury in a mouse model","volume":"281","author":"Desai","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1161\/HYPERTENSIONAHA.117.10094","article-title":"MicroRNA-221\/222 Family Counteracts Myocardial Fibrosis in Pressure Overload\u2013Induced Heart Failure","volume":"71","author":"Verjans","year":"2018","journal-title":"Hypertension"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/jcb.24075","article-title":"MiR-221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression","volume":"113","author":"Wang","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ejhf.244","article-title":"MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure","volume":"17","author":"Watson","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Esplugas, R., Arenas, M., Serra, N., Bell\u00e9s, M., Bonet, M., Gasc\u00f3n, M., Vallv\u00e9, J.-C., and Linares, V. (2019). Effect of radiotherapy on the expression of cardiovascular disease-related miRNA-146a, -155, -221 and -222 in blood of women with breast cancer. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0217443"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/micc.12124","article-title":"Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability","volume":"21","author":"Plein","year":"2014","journal-title":"Microcirculation"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1161\/CIRCULATIONAHA.111.021774","article-title":"Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: Current evidence and underlying mechanisms","volume":"124","author":"Scott","year":"2011","journal-title":"Circulation"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/embor.2010.117","article-title":"The ZEB\/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?","volume":"11","author":"Brabletz","year":"2010","journal-title":"EMBO Rep."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Beji, S., Milano, G., Scopece, A., Cicchillitti, L., Cencioni, C., Picozza, M., D\u2019Alessandra, Y., Pizzolato, S., Bertolotti, M., and Spaltro, G. (2017). Doxorubicin upregulates CXCR4 via miR-200c\/ZEB1-dependent mechanism in human cardiac mesenchymal progenitor cells. Cell Death Dis., 8.","DOI":"10.1038\/cddis.2017.409"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","article-title":"Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron","volume":"61","author":"Hrdina","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.bjp.0706953","article-title":"Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide","volume":"149","author":"Damrot","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/cdd.2011.42","article-title":"miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition","volume":"18","author":"Magenta","year":"2011","journal-title":"Cell Death Differ."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Carlomosti, F., D\u2019Agostino, M., Beji, S., Torcinaro, A., Rizzi, R., Zaccagnini, G., Maimone, B., Di Stefano, V., De Santa, F., and Cordisco, S. (2017). Oxidative Stress-Induced miR-200c Disrupts the Regulatory Loop among SIRT1, FOXO1, and eNOS. Antioxid. Redox Signal., 27.","DOI":"10.1089\/ars.2016.6643"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.4161\/cc.7.14.6267","article-title":"Emerging roles of SIRT1 in vascular endothelial homeostasis","volume":"7","author":"Potente","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1512326","DOI":"10.1155\/2019\/1512326","article-title":"miR-200a Attenuated Doxorubicin-Induced Cardiotoxicity through Upregulation of Nrf2 in Mice","volume":"2019","author":"Hu","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Vacchi-Suzzi, C., Bauer, Y., Berridge, B.R., Bongiovanni, S., Gerrish, K., Hamadeh, H.K., Letzkus, M., Lyon, J., Moggs, J., and Paules, R.S. (2012). Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040395"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1080\/15384101.2019.1673618","article-title":"miR-34b\/c regulates doxorubicin-induced myocardial cell injury through ITCH","volume":"18","author":"Zhang","year":"2019","journal-title":"Cell Cycle"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/00003495-200565070-00008","article-title":"Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy","volume":"65","author":"Scott","year":"2005","journal-title":"Drugs"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1161\/CIRCRESAHA.111.243592","article-title":"Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction","volume":"109","author":"Zhou","year":"2011","journal-title":"Circ. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0968-0004(96)10033-5","article-title":"Not all Shc\u2019s roads lead to Ras","volume":"21","author":"Bonfini","year":"1996","journal-title":"Trends. Biochem. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis","volume":"188","author":"Tarrio","year":"2012","journal-title":"J. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Baban, B., Liu, J.Y., Qin, X., Weintraub, N.L., and Mozaffari, M.S. (2015). Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124059"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1159\/000491896","article-title":"MicroRNA-29b Regulates the Mitochondria-Dependent Apoptotic Pathway by Targeting Bax in Doxorubicin Cardiotoxicity","volume":"48","author":"Jing","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Leger, K.J., Leonard, D., Nielson, D., de Lemos, J.A., Mammen, P.P.A., and Winick, N.J. (2017). Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy. J. Am. Heart Assoc., 6.","DOI":"10.1161\/JAHA.116.004653"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"13027","DOI":"10.1073\/pnas.0805038105","article-title":"Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis","volume":"105","author":"Sutherland","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCGENETICS.111.959841","article-title":"Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction","volume":"4","author":"Zile","year":"2011","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jacc.2013.09.041","article-title":"Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy","volume":"63","author":"Roncarati","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1161\/HYPERTENSIONAHA.109.144428","article-title":"Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes","volume":"55","author":"Liu","year":"2010","journal-title":"Hypertension (Dallas Tex. 1979)"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.phrs.2006.01.001","article-title":"Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice","volume":"53","author":"Kizaki","year":"2006","journal-title":"Pharmacol. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13014-016-0636-4","article-title":"Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer","volume":"11","author":"Dinh","year":"2016","journal-title":"Radiat. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e1754","DOI":"10.1038\/cddis.2015.89","article-title":"Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in \u03b2-adrenergic signaling and enhances apoptosis","volume":"6","author":"Castellano","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lfs.2016.09.006","article-title":"MiRNA-30e mediated cardioprotection of ACE2 in rats with Doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy","volume":"169","author":"Lai","year":"2017","journal-title":"Life Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","article-title":"Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death","volume":"74","author":"Oltvai","year":"1993","journal-title":"Cell"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12012-018-9457-z","article-title":"Serum miR-30c Level Predicted Cardiotoxicity in Non-small Cell Lung Cancer Patients Treated with Bevacizumab","volume":"18","author":"Zhou","year":"2018","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"14511","DOI":"10.3390\/ijms160714511","article-title":"MiR-21 Protected Cardiomyocytes against Doxorubicin-Induced Apoptosis by Targeting BTG2","volume":"16","author":"Tong","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Simone, N.L., Soule, B.P., Ly, D., Saleh, A.D., Savage, J.E., Degraff, W., Cook, J., Harris, C.C., Gius, D., and Mitchell, J.B. (2009). Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006377"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/s41388-018-0178-3","article-title":"miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy","volume":"37","author":"Xi","year":"2018","journal-title":"Oncogene"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/FJC.0b013e3181f8d173","article-title":"MicroRNAs: Redefining Mechanisms in Cardiac Disease","volume":"56","author":"Dorn","year":"2010","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ng1725","article-title":"The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation","volume":"38","author":"Chen","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature03817","article-title":"Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis","volume":"436","author":"Zhao","year":"2005","journal-title":"Nature"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/CS20090645","article-title":"A translational study of circulating cell-free microRNA-1 in acute myocardial infarction","volume":"119","author":"Cheng","year":"2010","journal-title":"Clin. Sci. (Lond.)"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jat.3044","article-title":"Plasma miR-208 as a useful biomarker for drug-induced cardiotoxicity in rats","volume":"35","author":"Nishimura","year":"2015","journal-title":"J. Appl. Toxicol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Rigaud, V.O.-C., Ferreira, L.R.P., Ayub-Ferreira, S.M., \u00c1vila, M.S., Brand\u00e3o, S.M.G., Cruz, F.D., Santos, M.H.H., Cruz, C.B.B.V., Alves, M.S.L., and Issa, V.S. (2017). Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. Oncotarget, 8.","DOI":"10.18632\/oncotarget.14355"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.33549\/physiolres.933399","article-title":"Changes of microRNA-1, -15b and -21 levels in irradiated rat hearts after treatment with potentially radioprotective drugs","volume":"65","author":"Kura","year":"2016","journal-title":"Physiol. Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/cvr\/cvp232","article-title":"MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: A new mechanism for ischaemic cardioprotection","volume":"84","author":"Lu","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1152\/japplphysiol.00932.2006","article-title":"MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy","volume":"102","author":"McCarthy","year":"2007","journal-title":"J. Appl. Physiol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1242\/jcs.010728","article-title":"The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes","volume":"120","author":"Xu","year":"2007","journal-title":"J. Cell Sci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1373\/clinchem.2009.125310","article-title":"Plasma miR-208 as a Biomarker of Myocardial Injury","volume":"55","author":"Ji","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3389\/fgene.2018.00734","article-title":"miR-499-5p Attenuates Mitochondrial Fission and Cell Apoptosis via p21 in Doxorubicin Cardiotoxicity","volume":"9","author":"Wan","year":"2018","journal-title":"Front. Genet."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/156652412798376170","article-title":"miR221\/222 in cancer: Their role in tumor progression and response to therapy","volume":"12","author":"Garofalo","year":"2012","journal-title":"Curr. Mol. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yjmcc.2011.11.008","article-title":"Cell-specific effects of miR-221\/222 in vessels: Molecular mechanism and therapeutic application","volume":"52","author":"Liu","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cdd.2014.187","article-title":"MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27\/CDK2\/mTOR axis","volume":"22","author":"Su","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"10402","DOI":"10.18632\/oncotarget.23781","article-title":"Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients","volume":"9","author":"Lieb","year":"2018","journal-title":"Oncotarget"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Tao, L., Bei, Y., Zhou, Y., Xiao, J., and Li, X. (2015). Non-coding RNAs in cardiac regeneration. Oncotarget, 6.","DOI":"10.18632\/oncotarget.6073"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2012\/549875","article-title":"miR-320 Regulates Glucose-Induced Gene Expression in Diabetes","volume":"2012","author":"Feng","year":"2012","journal-title":"ISRN Endocrinol."},{"key":"ref_151","first-page":"192","article-title":"miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway","volume":"8","author":"Yin","year":"2016","journal-title":"Aging (Albany. N.Y.)"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/cvr\/27.7.1368","article-title":"Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor I","volume":"27","author":"Ambler","year":"1993","journal-title":"Cardiovasc. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/01.RES.83.5.516","article-title":"Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I","volume":"83","author":"Wang","year":"1998","journal-title":"Circ. Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000455823","article-title":"Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview","volume":"62","author":"Menna","year":"2017","journal-title":"Chemotherapy"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00280-019-03910-6","article-title":"Current status of nanomedicine in the chemotherapy of breast cancer","volume":"84","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/mnfr.201500945","article-title":"Combination chemoprevention with grape antioxidants","volume":"60","author":"Singh","year":"2016","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"917606","DOI":"10.1155\/2015\/917606","article-title":"Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors","volume":"2015","author":"Kirkham","year":"2015","journal-title":"J. Oncol."},{"key":"ref_158","first-page":"276","article-title":"Comparison of the effectiveness of (+\/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles","volume":"45","author":"Herman","year":"1985","journal-title":"Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.yjmcc.2015.12.021","article-title":"Cardioprotective effects of inorganic nitrate\/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane","volume":"91","author":"Hroch","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0024-3205(99)00362-8","article-title":"Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats","volume":"65","author":"Matsui","year":"1999","journal-title":"Life Sci."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2007.12.010","article-title":"Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart","volume":"44","author":"Rienzo","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.jacc.2012.02.092","article-title":"The usefulness of brain natriuretic peptide in complex congenital heart disease: A systematic review","volume":"60","author":"Eindhoven","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jacc.2009.12.044","article-title":"A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure","volume":"55","author":"Gao","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/eurjhf\/hfq152","article-title":"Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses","volume":"13","author":"Jabbour","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1161\/CIRCULATIONAHA.113.002203","article-title":"An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential","volume":"128","author":"Jay","year":"2013","journal-title":"Circulation"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Milano, G., Biemmi, V., Lazzarini, E., Balbi, C., Ciullo, A., Bolis, S., Ameri, P., Di Silvestre, D., Mauri, P., and Barile, L. (2019). Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin\/trastuzumab-induced cardiac toxicity. Cardiovasc. Res.","DOI":"10.1093\/cvr\/cvz108"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/3\/704\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:07:25Z","timestamp":1760173645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/3\/704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":167,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["cancers12030704"],"URL":"https:\/\/doi.org\/10.3390\/cancers12030704","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]}}}